Novartis Confirms First Fatality Following Use of MS Drug Gilenya

Drug Industry Daily
A A
A 59-year-old multiple sclerosis (MS) patient in the U.S. died abruptly the day after initiating Novartis’ relapsing-remitting MS treatment Gilenya, the Swiss-owned company says.

To View This Article:

Login

Subscribe To Drug Industry Daily